33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Allogeneic stem cell transplant and CD30 directed CART cell therapies are associated with improved survival in classical Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: Real world analysis from 14 US academic centers
    Meeting Abstract

    Voorhees, T.; Grover, N. S.; McLaughlin, E.; Florindez, J. A.; Moyo, T. K.; Reves, H.; Sumransub, N.; Deshpande, S.; Rose, A.; Duarte, C.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Multicenter study of mantle cell lymphoma outcomes following first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy
    Meeting Abstract

    Wang, Y.; Larson, M. C.; Hwang, S. R.; Kumar, A.; Joseph, A.; Hill, B. T.; Brooks, T. R.; Bond, D. A.; Maddocks, K. J.; Danilov, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Predictors of cytokine release syndrome and neurotoxicity in patients with large B-cell lymphoma and their impact on survival
    Meeting Abstract

    Shouval, R.; Strouse, C.; Kim, S.; Oloyede, T.; Ahmed, S.; Awan, F. T.; Bachanova, V.; Badar, T.; Barba, P.; Beitinjaneh, A. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • ALLO-647 for lymphodepletion in the allogeneic CAR T setting: Safety experience with ALLO-501/501A in patients (pts) with relapsed/refractory (r/r) large B-cell and follicular lymphomas
    Meeting Abstract

    Locke, F. L.; Munoz, J. L.; Tees, M. T.; Lekakis, L. J.; Eradat, H. A.; de Vos, S.; Nath, R.; Stevens, D. A.; Malik, S. A.; Shouse, G. P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Real-world evidence in the United States (US) of the impact of bridging therapy prior to axicabtagene ciloleucel (axi-cel) for the treatment of relapsed or refractory large B-cell lymphoma (R/R LBCL)
    Meeting Abstract

    Cook, M. R.; Shouval, R.; Perales, M. A.; Bezerra, E.; Niu, A.; Dahiya, S.; Nastoupil, L. J.; Jacobson, C. A.; Budde, L. E.; Olson, A. L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Valemetostat for relapsed or refractory peripheral T-cell lymphomas: Primary results from a phase 1 trial
    Meeting Abstract

    Jacobsen, E.; Maruyama, D.; Porcu, P.; Tobinai, K.; Allen, P. B.; Ishitsuka, K.; Tsukasaki, K.; Kusumoto, S.; Foss, F. M.; Yamauchi, N.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Asciminib (ASC) in combination with Imatinib (IMA), nilotinib (NIL), or dasatinib (DAS) may be a potential treatment (Tx) option in patients (pts) with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase or accelerated phase (Ph + CML-CP/AP): Final results from the asciminib phase 1 study
    Meeting Abstract

    Cortes, J.; Lang, F.; Rea, D.; Hochhaus, A.; Breccia, M.; Goh, Y. T.; Heinrich, M. C.; Hughes, T. P.; Janssen, J. J. W. M.; le Coutre, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A simple prediction model of outcomes after allogeneic hematopoietic stem cell transplant (HCT) in myelodysplastic syndromes using HCT-comorbidity index, cytogenetic risk, and platelet count
    Meeting Abstract

    Frumm, S. M.; Kim, H. T.; Kelkar, A. H.; Ho, V. T.; Gooptu, M.; Gibson, C. J.; Koreth, J.; Shapiro, R. M.; Romee, R.; Nikiforow, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of idecabtagene vicleucel (ide-cel) in patients with clinical high-risk newly diagnosed multiple myeloma (NDMM) with an inadequate response to frontline autologous stem cell transplantation (ASCT): KarMMa-2 cohort 2c extended follow-up
    Meeting Abstract

    Dhodapkar, M. V.; Alsina, M.; Berdeja, J. G.; Patel, K. K.; Richard, S.; Vij, R.; Leleu, X.; Egan, D. N.; Bergsagel, P. L.; Reshef, R.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Pembrolizumab (pembro) in children and young adults with low-risk classical Hodgkin lymphoma (cHL) with slow early response (SER) to front-line chemotherapy (chemo): Early results from the phase 2 KEYNOTE-667 study
    Meeting Abstract

    Roth, L. G.; Keller, F.; Toledo, M. M.; Castellino, S. M.; Forlenza, C. J.; Catalan, M. A.; Krystal, J.; Lamble, A.; Rao, A. V.; Morales, F. M.; more...
    Blood (2023)

    Fulltext@MSK | Save